Cancer profiling
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in the world.
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in the world. Currently, it is staged preoperatively by radiographic tests, and postoperatively by pathological evaluation of available surgical specimens. However, present staging methods do not accurately identify occult metastases, which have a direct affect on clinical management.
A team of scientists has performed an experiment to distinguish stages of colorectal cancer.1 Sera from 103 patients with colorectal adenocarcinoma were analysed by proton nuclear magnetic resonance spectroscopy and gas chromatography–mass spectroscopy.
The serum metabolomic profile was found to change substantially with metastasis, while the site of disease also appeared to affect the pattern of circulating metabolites. The team concluded that this novel observation could be of value in enhancing staging accuracy and selecting patients for treatment, but that additional study is ultimately required. Early identification of metastases isolated to the liver may mean surgery is an option, while more widely disseminated disease could be treated with palliative chemotherapy.
1. Oliver F. Bathe et al.,Genome Medicine4(42), doi: 10.1186gm341 (2012).
This story originally appeared in The Column. Click here to view that issue.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
